This company listing is no longer active
Indivior (INDV) Stock Overview
Engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
INDV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Indivior PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£12.38 |
| 52 Week High | UK£12.64 |
| 52 Week Low | UK£5.55 |
| Beta | 0.26 |
| 1 Month Change | 22.82% |
| 3 Month Change | 51.81% |
| 1 Year Change | 25.43% |
| 3 Year Change | -22.91% |
| 5 Year Change | 80.20% |
| Change since IPO | 65.07% |
Recent News & Updates
Recent updates
Indivior PLC (LON:INDV) Held Back By Insufficient Growth Even After Shares Climb 26%
Indivior PLC ( LON:INDV ) shareholders would be excited to see that the share price has had a great month, posting a...
SUBLOCADE Investments Will Improve Patient And Physician Experience
Commercial investments and label updates for SUBLOCADE are expected to boost revenue growth and enhance patient and physician experience.Results: Indivior PLC Exceeded Expectations And The Consensus Has Updated Its Estimates
A week ago, Indivior PLC ( LON:INDV ) came out with a strong set of quarterly numbers that could potentially lead to a...The Market Doesn't Like What It Sees From Indivior PLC's (LON:INDV) Revenues Yet As Shares Tumble 26%
Indivior PLC ( LON:INDV ) shareholders won't be pleased to see that the share price has had a very rough month...A Piece Of The Puzzle Missing From Indivior PLC's (LON:INDV) 35% Share Price Climb
Those holding Indivior PLC ( LON:INDV ) shares would be relieved that the share price has rebounded 35% in the last...Positive Sentiment Still Eludes Indivior PLC (LON:INDV) Following 26% Share Price Slump
To the annoyance of some shareholders, Indivior PLC ( LON:INDV ) shares are down a considerable 26% in the last month...Indivior PLC's (LON:INDV) Shares Leap 37% Yet They're Still Not Telling The Full Story
Indivior PLC ( LON:INDV ) shareholders are no doubt pleased to see that the share price has bounced 37% in the last...Indivior PLC's (LON:INDV) Shares Not Telling The Full Story
With a price-to-sales (or "P/S") ratio of 2.2x Indivior PLC ( LON:INDV ) may be sending bullish signals at the moment...Shareholders May Not Be So Generous With Indivior PLC's (LON:INDV) CEO Compensation And Here's Why
Key Insights Indivior will host its Annual General Meeting on 9th of May CEO Mark Crossley's total compensation...We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...The Market Lifts Indivior PLC (LON:INDV) Shares 26% But It Can Do More
Indivior PLC ( LON:INDV ) shares have continued their recent momentum with a 26% gain in the last month alone. Looking...Are Investors Undervaluing Indivior PLC (LON:INDV) By 50%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Indivior fair value estimate is UK£23.62 Indivior is estimated...We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Indivior (LON:INDV) Has A Pretty Healthy Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Shareholder Returns
| INDV | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 3.3% | -5.5% | -1.5% |
| 1Y | 25.4% | 16.2% | 17.2% |
Return vs Industry: INDV exceeded the UK Pharmaceuticals industry which returned -7.6% over the past year.
Return vs Market: INDV exceeded the UK Market which returned 8.4% over the past year.
Price Volatility
| INDV volatility | |
|---|---|
| INDV Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in GB Market | 11.7% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: INDV has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: INDV's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 1,041 | Joe Ciaffoni | www.indivior.com |
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD).
Indivior PLC Fundamentals Summary
| INDV fundamental statistics | |
|---|---|
| Market cap | UK£2.14b |
| Earnings (TTM) | -UK£46.14m |
| Revenue (TTM) | UK£870.68m |
Is INDV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INDV income statement (TTM) | |
|---|---|
| Revenue | US$1.17b |
| Cost of Revenue | US$215.00m |
| Gross Profit | US$955.00m |
| Other Expenses | US$1.02b |
| Earnings | -US$62.00m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 31, 2025
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 81.62% |
| Net Profit Margin | -5.30% |
| Debt/Equity Ratio | -115.4% |
How did INDV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/26 17:17 |
| End of Day Share Price | 2025/07/24 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Indivior Pharmaceuticals, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Graham Glyn Parry | BofA Global Research |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |
| Brandon Folkes | H.C. Wainwright & Co. |